|1.||Stolz, Uwe: 3 articles (11/2015 - 06/2012)|
|2.||Selvendiran, Karuppaiyah: 3 articles (01/2013 - 05/2010)|
|3.||Kuppusamy, Periannan: 3 articles (01/2013 - 05/2010)|
|4.||Rivera, Brian K: 3 articles (01/2013 - 05/2010)|
|5.||Gaither, Joshua B: 2 articles (11/2015 - 09/2014)|
|6.||Sakles, John C: 2 articles (11/2015 - 06/2012)|
|7.||Ennis, Joshua: 2 articles (11/2015 - 09/2014)|
|8.||Strandberg, Timo E: 2 articles (03/2013 - 02/2011)|
|9.||Pitkala, Kaisu H: 2 articles (03/2013 - 02/2011)|
|10.||Uusvaara, Juho: 2 articles (03/2013 - 02/2011)|
08/11/2011 - "These results suggest that antioxidant-conjugated DAPs will be useful as a safe and effective anticancer agent for cancer therapy."
05/01/2010 - "The results suggest that the antioxidant-conjugated DAPs will be useful as safe and effective anticancer agents for cancer therapy."
06/01/2012 - "In this study, the values of entrance skin dose (ESD), dose area products (DAPs), energy imparted (EI), whole-body dose, effective dose and risk of childhood cancer were estimated using three methods including direct method [using thermoluminescence dosimetry (TLD) chips], indirect method (using tube output) and Monte Carlo (MC) method (using MCNP4C code). "
01/01/2014 - "Data will be acquired from databases maintained by participating DAPs and the provincial cancer agency, and confirmed by and supplemented with review of medical records. "
11/08/2006 - "This investigation was conducted on the production mechanism of DAPs, using (C57BL/6NxDBA/2N)F(1) mice and the P388D(1) (lymphoid) tumor system. "
|2.||Prostatic Neoplasms (Prostate Cancer)
05/01/2010 - "The goal of the study was to evaluate the proof-of-concept anticancer-versus-antioxidant efficacy of the DAPs using a number of cancerous (breast, colon, head and neck, liver, lung, ovarian, and prostate cancer) and noncancerous (smooth muscle, aortic endothelial, and ovarian surface epithelial) human cell lines. "
01/01/2015 - "Topical DAPS is more effective than DHPS in preventing inflammatory signs (increased vascular permeability, edema, leukocyte infiltration, MPO activation) caused by contact dermatitis induction in rat ears. "
11/01/2015 - "The odds ratios with 95% confidence intervals (CIs) of finding DAPs in the FPH/SED group compared with the NPH/SED group was blood = 5.80 (95% CI, 3.89-8.63), vomit = 2.01 (95% CI, 1.25-3.21), short neck = 2.67 (95% CI, 1.39-5.03), neck immobility = 2.52 (95% CI, 1.72-3.67), airway edema = 10.52 (95% CI, 4.15-29.92), facial trauma = 4.64 (95% CI, 2.91-7.39), and large tongue = 3.08 (95% CI, 1.75-5.40). "
09/01/2014 - "Prevalence of DAPs in cases with FP-ETI was obesity 13.0%, large tongue 18.0%, short neck 13%, small mandible 4.3%, cervical immobility 49.7%, blood in airway 57.8%, vomitus in airway 23.0%, airway edema 12.4%, and facial or neck trauma 32.9%. "
09/01/2014 - "Physicians performing ETI evaluated each case for the presence of DAPs, including blood/emesis, facial/neck trauma, airway edema, spinal immobilization, short neck, and tongue enlargement. "
06/01/2012 - "DAPs included: cervical immobility, obesity, small mandible, large tongue, short neck, blood or vomit in the airway, tracheal edema, secretions, and facial or neck trauma. "
08/01/2010 - "Using an experimental model of infective endocarditis and two DAPs/DAPr strain pairs, we demonstrated that (i) OX monotherapy was ineffective at clearing DAPr strains from any target tissue in this model (heart valve, kidneys, or spleen) and (ii) DAP-OX combination therapy was highly effective in DAPr strain clearances from these organs. "
|5.||Contact Dermatitis (Eczema, Contact)
|1.||Proteins (Proteins, Gene)
|5.||Sarcoglycans (beta Sarcoglycan)
|6.||Human Immunodeficiency Virus Proteins
|8.||Biological Markers (Surrogate Marker)
|10.||Thymidine Monophosphate (TMP)
|1.||Home Nursing (Nursing, Home)